Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer.
View / Open Files
Authors
Jenks, Andrew D
Vyse, Simon
Wong, Jocelyn P
Kostaras, Eleftherios
Keller, Deborah
Burgoyne, Thomas
Shoemark, Amelia
Tsalikis, Athanasios
Michaelis, Martin
Cinatl, Jindrich
Huang, Paul H
Tanos, Barbara E
Publication Date
2018-06-05Journal Title
Cell Reports
ISSN
2211-1247
Publisher
Elsevier
Volume
23
Issue
10
Pages
3042-3055
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Jenks, A. D., Vyse, S., Wong, J. P., Kostaras, E., Keller, D., Burgoyne, T., Shoemark, A., et al. (2018). Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer.. Cell Reports, 23 (10), 3042-3055. https://doi.org/10.1016/j.celrep.2018.05.016
Abstract
Primary cilia are microtubule-based organelles that detect mechanical and chemical stimuli. Although cilia house a number of oncogenic molecules (including Smoothened, KRAS, EGFR, and PDGFR), their precise role in cancer remains unclear. We have interrogated the role of cilia in acquired and de novo resistance to a variety of kinase inhibitors, and found that, in several examples, resistant cells are distinctly characterized by an increase in the number and/or length of cilia with altered structural features. Changes in ciliation seem to be linked to differences in the molecular composition of cilia and result in enhanced Hedgehog pathway activation. Notably, manipulating cilia length via Kif7 knockdown is sufficient to confer drug resistance in drug-sensitive cells. Conversely, targeting of cilia length or integrity through genetic and pharmacological approaches overcomes kinase inhibitor resistance. Our work establishes a role for ciliogenesis and cilia length in promoting cancer drug resistance and has significant translational implications.
Keywords
FGFR, Hedgehog pathway, cilia, kinase inhibitor, resistance
Sponsorship
This research was partly funded by the Institute of Cancer Research and by grants from Sarcoma UK (to B.E.T. [14.2014] and P.H.H. [3.2014]), Kent Cancer Trust (to M.M.), Hilfe fuer Krebskranke Kinder Frankfurt e.V. and Frankfurter Stiftung fuer Krebskranke Kinder (to J.C.), CRUK-CI Core Grant (C14303/A17197), and S.H.D. Fellowship (Wellcome Trust/Royal Society [107609]) (to M.D.R.). B.E.T. was supported by an ICR fellowship.
Funder references
Wellcome Trust (107609/Z/15/Z)
Cancer Research UK (C14303/A17197)
Identifiers
External DOI: https://doi.org/10.1016/j.celrep.2018.05.016
This record's URL: https://www.repository.cam.ac.uk/handle/1810/285895
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk
The following licence files are associated with this item: